First Tracks (TRAX) CMO Paul Lizzul Receives 60,492-Share PSU Award

What Happened
Paul F. Lizzul, Chief Medical Officer of First Tracks Biotherapeutics, was granted 60,492 performance-based restricted stock units (PSUs) on August 2, 2026. The award is reported as a derivative acquisition at $0.00 (no cash paid). Each PSU represents a conditional right to one share of common stock and will convert into shares if performance conditions are met and the units vest.

Key Details

• Transaction date: August 2, 2026; Report filed August 5, 2026. Report shows acquisition code "A" (award/grant) and price $0.00.
• Amount: 60,492 PSUs (each PSU = one share upon settlement).
• Vesting/settlement: PSUs vest and settle over two years — 50% vests August 2, 2027 and 50% vests July 1, 2028 — subject to continued service on each vesting date (Footnotes F1–F3).
• Performance condition: PSUs were earned upon certification of performance criteria by the Compensation Committee on August 2, 2026 (Footnote F1).
• Shares owned after transaction: Not specified in the provided filing excerpt.
• Filing timeliness: Filing date is August 5, 2026; the filing shows the transaction and date but no late-filing indicator was provided in the details you supplied.

Context
This was a compensation award (performance-based RSUs), not an open-market buy or sale. No cash changed hands at grant; the economic value depends on future achievement of performance goals and share price at settlement. For many retail investors, awards reflect executive compensation/retention rather than an immediate personal investment signal.